Delving into the Latest Updates on LF-0376 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Mechanism-

Therapeutic Areas

NeoplasmsImmune System DiseasesDigestive System Disorders+ [2]

Active Indication

Advanced Malignant Solid NeoplasmColorectal CancerLiver Cancer+ [3]

Inactive Indication-

Originator Organization

Shenzhen Lingfang Biomedical Technology Co., Ltd.

Active Organization

Shenzhen Lingfang Biomedical Technology Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的： 1、评价LF0376片的安全性和耐受性； 2、确定LF0376片的最大耐受剂量（MTD）和后续研究的合适推荐剂量（RD）。次要目的： 1、评价LF0376片的药代动力学（PK）特征； 2、初步评价LF0376片治疗结直肠癌、胰腺癌、肝癌等晚期实体瘤和淋巴瘤患者的有效性

[Translation]

Main objectives: 1. Evaluate the safety and tolerability of LF0376 tablets; 2. Determine the maximum tolerated dose (MTD) of LF0376 tablets and the appropriate recommended dose (RD) for subsequent studies. Secondary objectives: 1. Evaluate the pharmacokinetic (PK) characteristics of LF0376 tablets; 2. Preliminary evaluation of the effectiveness of LF0376 tablets in the treatment of patients with advanced solid tumors and lymphomas such as colorectal cancer, pancreatic cancer, and liver cancer

Start Date20 Jun 2022

Sponsor / Collaborator

Shenzhen Lingfang Biomedical Technology Co., Ltd.

100 Clinical Results associated with LF-0376

Login to view more data

100 Translational Medicine associated with LF-0376

Login to view more data

100 Patents (Medical) associated with LF-0376

Login to view more data

100 Deals associated with LF-0376

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	CN	Shenzhen Lingfang Biomedical Technology Co., Ltd.	20 Jun 2022
Colorectal Cancer	Phase 1	CN	Shenzhen Lingfang Biomedical Technology Co., Ltd.	20 Jun 2022
Liver Cancer	Phase 1	CN	Shenzhen Lingfang Biomedical Technology Co., Ltd.	20 Jun 2022
Lymphoma	Phase 1	CN	Shenzhen Lingfang Biomedical Technology Co., Ltd.	20 Jun 2022
Pancreatic Cancer	Phase 1	CN	Shenzhen Lingfang Biomedical Technology Co., Ltd.	20 Jun 2022
Diffuse Large B-Cell Lymphoma	IND Approval	CN	Shenzhen Lingfang Biomedical Technology Co., Ltd.	25 Jan 2024